Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 412,629 shares of CYTK, which is worth approximately $12.8 Million. The most recent transaction as insider was on May 16, 2023, when has been sold 12,500 shares (Common Stock) at a price of $37.41 per share, resulting in proceeds of $467,624. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 413K

2.3% 3M change

10.54% 12M change

Total Value Held $12.8 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 16 2023	SELL Open market or private sale	$467,624 $37.41 p/Share	12,500 Reduced 2.76%	441,058 Common Stock
May 16 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,558 Common Stock
Apr 28 2023	SELL Open market or private sale	$471,000 $37.68 p/Share	12,500 Reduced 2.76%	441,058 Common Stock
Apr 28 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,558 Common Stock
Apr 14 2023	SELL Open market or private sale	$445,125 $35.61 p/Share	12,500 Reduced 2.76%	441,058 Common Stock
Apr 14 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,558 Common Stock
Mar 28 2023	SELL Open market or private sale	$438,124 $35.05 p/Share	12,500 Reduced 2.76%	441,058 Common Stock
Mar 28 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,558 Common Stock
Mar 15 2023	SELL Open market or private sale	$465,750 $37.26 p/Share	12,500 Reduced 2.76%	441,058 Common Stock
Mar 15 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,558 Common Stock
Mar 06 2023	SELL Payment of exercise price or tax liability	$465,647 $39.13 p/Share	11,900 Reduced 3.21%	358,558 Common Stock
Mar 06 2023	SELL Open market or private sale	$499,250 $39.94 p/Share	12,500 Reduced 3.26%	370,458 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	82,500 Added 15.76%	441,058 Common Stock
Mar 06 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 3.16%	382,958 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$1,295,870 $39.6 p/Share	32,724 Reduced 8.12%	370,458 Common Stock
Feb 16 2023	SELL Payment of exercise price or tax liability	$142,539 $44.13 p/Share	3,230 Reduced 0.79%	403,182 Common Stock
Jan 17 2023	SELL Open market or private sale	$424,300 $42.43 p/Share	10,000 Reduced 2.4%	406,412 Common Stock
Jan 17 2023	BUY Exercise of conversion of derivative security	$96,500 $9.65 p/Share	10,000 Added 2.35%	416,412 Common Stock
Jan 04 2023	SELL Open market or private sale	$442,400 $44.24 p/Share	10,000 Reduced 2.4%	406,412 Common Stock
Jan 04 2023	BUY Exercise of conversion of derivative security	$96,500 $9.65 p/Share	10,000 Added 2.35%	416,412 Common Stock
Dec 21 2022	SELL Open market or private sale	$439,200 $43.92 p/Share	10,000 Reduced 2.4%	406,412 Common Stock
Dec 21 2022	BUY Exercise of conversion of derivative security	$96,500 $9.65 p/Share	10,000 Added 2.35%	416,412 Common Stock
Dec 05 2022	SELL Open market or private sale	$393,000 $39.3 p/Share	10,000 Reduced 2.4%	406,412 Common Stock
Dec 05 2022	BUY Exercise of conversion of derivative security	$96,500 $9.65 p/Share	10,000 Added 2.35%	416,412 Common Stock
Nov 21 2022	SELL Open market or private sale	$408,900 $40.89 p/Share	10,000 Reduced 2.4%	406,089 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account